This site is intended only for healthcare professionals resident in Egypt 

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact Us

Menu

Close

Clinical Information Clinical Information Burden of meningococcal disease Serogroup distribution Nimenrix® immunogenicity Nimenrix® persistence Nimenrix® dose and administration Real-world impact Summary Important Safety Information Abbreviated Prescribing Information Support and Services Support and Services VideosWebinarsMaterialsSelf-detail Presentations

Nimenrix® in a nutshell

BROAD AGE INDICATION2
MenACWY-TT vaccine with demonstrated seroprotection and approved for use from age 6 weeks with no upper age limit

PERSISTENCE2
MenACWY-TT vaccine with antibody persistence evaluated for up to 10 years

HIGH-RISK POPULATION2
MenACWY-TT vaccine shown to be immunogenic in immunocompromised population, like patients with anatomical or functional asplenia

IMMUNOGENIC2
Proven non-inferior to monovalent MenC vaccines

DOSING AND COADMINISTRATION2
Nimenrix® offers coadministration with other routine immunisations for infants, toddlers, and adolescents

Nimenrix® can be prepared and administered in a few easy steps

SAFETY3
Safety has been evaluated in more than 10,000 individuals in clinical trials
  
Find out moreLoading
Find out moreLoading
Find out moreLoading
MenACWY-TT, Meningococcal serogroup A, C, W, and Y tetanus toxoid conjugate vaccine.

References:
  1. Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777-779.
  2. Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine). Egyptian Drug Authority leaflet approval date: 19/10/2022 Revision date: May 2022.
  3. Presa J, Findlow J, Vojicic J, Williams S, Serra L. Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review. Infect Dis Ther. 2019;8(3):307-333.
Click here for Nimenrix® Prescribing Information Loading

Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025

PP-NIM-EGY-0056

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


PP-UNP-EGY-0241
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 

If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
 

I confirm that I am a healthcare professional resident in Egypt.
 

PP-UNP-EGY-0241

Yes No
You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
 
PP-UNP-EGY-0241
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

PP-UNP-EGY-0241